How Gala Health prices care, what it prescribes, and where the fine print matters
Gala Health is the current consumer brand used for a mixed telehealth catalog. Its legal pages identify AI Coaching Inc., doing business as Gala GLP-1, as the platform operator. Gala says it provides administrative and technology services rather than medical care. Independent clinicians affiliated with OpenLoop medical groups and other practices make prescribing decisions, while third-party pharmacies dispense medication.
The main weight-loss offer includes compounded semaglutide and tirzepatide. Gala's dedicated product page lists both ingredients, says all doses are included, and displays $179 per month on a yearly subscription. The homepage FAQ separately lists $199 per month on a three-month plan. That is useful plan-level disclosure, but the site does not show the yearly plan's upfront charge, whether it bills monthly under a commitment, or a current month-to-month rate.
The compact therapy cards use $179 per month because that is Gala's published annual-plan monthly figure. The notes keep the commitment visible. A reader should not interpret the card as a cancel-anytime monthly price. Before paying, confirm the amount due at checkout, the minimum term, the renewal date, the price after twelve months, and whether switching between semaglutide and tirzepatide changes any charge.
Gala's $149 microdosing program is a lower-dose tirzepatide-based protocol, not a new medication. It remains an editorial detail under tirzepatide. Gala promotes this program for energy, focus, sleep, metabolic resilience, and fewer gastrointestinal effects, but it does not provide a trial of the exact low-dose compounded protocol. Results from standard-dose tirzepatide trials cannot be assumed to establish those specific claims.
The branded option is Ozempic at a $1,299 monthly cash price. Gala correctly identifies it as semaglutide and says insurance may reduce the cost. Its weight-loss positioning still requires precision: Ozempic is FDA approved for specific type 2 diabetes, cardiovascular, and kidney-risk indications. The current label does not include chronic weight management, so use solely for weight loss is off label even though the finished Ozempic product is FDA approved.
The HRT program starts at $69 per month and advertises medication, clinician review, symptom check-ins, dose adjustments, messaging, and shipping. Gala names estradiol pills or patches, vaginal estradiol, and micronized progesterone. Vaginal estradiol is consolidated under estradiol because route does not create a different active ingredient. The unnamed nonhormonal pathway stays outside the comparison catalog until Gala names the medication.
Neither estradiol nor progesterone receives the $69 figure on its card. Gala does not state whether that price covers one medication, a combination, a particular route, a starter month, or every dose. FDA notes that menopausal hormone therapy can help selected patients but has benefits and risks that depend on the individual, route, dose, and medical history. Confirm the exact product, whether it is an FDA-approved finished drug or a compound, and the monitoring plan.
The longevity catalog contains subcutaneous NAD+ and sermorelin. Each costs $199 for a 28-day supply, or about $118 per month on a twelve-month plan costing $1,417 upfront. The therapy card shows only the compact $118 monthly equivalent, while the notes retain the total and 28-day supply unit. Twelve 28-day supplies cover 336 days, so that package should not be silently compared with a full 365-day year.
Gala markets NAD+ for cellular energy, DNA repair, cognition, and immune support. NAD+ participates in cellular processes, but that biochemical role does not by itself establish that Gala's injected product produces the promoted outcomes. Gala's own longevity page says there is no clinical trial for the compound bundle. Patients should ask what outcome is being treated, what evidence supports the route and dose, and how benefit and adverse effects will be assessed.
Sermorelin is marketed for sleep, recovery, and athletic performance through a five-nights-per-week injection protocol. FDA review records say the former Geref approvals were withdrawn after production ended, and their former uses do not create an approved adult-longevity indication. Gala's current product should be treated as a compounded prescription with an individualized rationale, not as an FDA-approved anti-aging therapy.
The clinician pathway is convenient. Weight-loss and HRT users complete an online questionnaire, and a live video may be required depending on the medication, patient, or state. Gala describes longevity review as asynchronous and says the initial visit can support one month plus two refills, followed by a quarterly questionnaire. A prescription is never guaranteed, and the provider may ask follow-up questions or decline care.
Gala says licensed providers and GLP-1 access are available across all fifty states. The terms still make availability dependent on independent clinicians, pharmacies, and applicable law. The public pages do not identify the clinician who will serve a particular state. Patients should verify the assigned clinician's name, professional role, and active state license before treatment.
The partner-pharmacy network is also unnamed. Gala says compounded products come from licensed pharmacies and ingredients from regulated suppliers, but it does not identify the actual pharmacy, formulation, concentration, additives, batch test, or certificate before intake. Those facts matter more than a broad network claim. Confirm the pharmacy license, active ingredient, concentration, prescribed milligrams, syringe units, beyond-use date, storage range, and testing for the dispensed product.
Gala's product page says compounded medications are made under FDA oversight. That phrase is too broad without qualification. FDA does not approve or license compounding pharmacies, and compounded finished products are not reviewed before marketing for safety, effectiveness, or quality. FDA also warns telehealth companies not to imply that a compound is the same as an approved drug or clinically proven to produce the same result.
Current federal compounding policy adds another layer. Semaglutide and tirzepatide are no longer on the national shortage list, and broad shortage-related enforcement periods have ended. Patient-specific compounding may still qualify under applicable law, but regular production of essentially copies is restricted. The prescriber and pharmacy should be able to explain the individual clinical need for the chosen compound.
Gala advertises free, discreet shipping and a path from assessment to medication in about a week. The refund policy gives a practical remedy for damaged or incorrect medication: damaged items may be replaced with evidence, and incorrect medication is replaced by the pharmacy. The public documents do not publish one guaranteed processing window, temperature-excursion standard, carrier-delay process, or reporting deadline.
Support is advertised as available around the clock, with provider messaging included. The legal pages list team@galaglp1.com and text-message help, but they do not publish a general support telephone number, a complete schedule for every channel, or response-time targets. Administrative support is not an emergency service, and urgent symptoms should use appropriate emergency care.
Cancellation is allowed, but timing controls the next charge. Gala requires the request at least seventy-two hours before the billing date. Missing that cutoff means another charge and cancellation after the next cycle. Refunds are generally limited to medical disqualification, and past billing cycles are not refunded. The longevity page also says the customer is charged at checkout before provider review, with a full refund if the clinician cannot prescribe.
Most Gala programs are cash-pay and do not require insurance. The site advertises HSA and FSA acceptance and offers an insurance coverage check for Ozempic. The refund policy says a subscription may include lab services but that covered services, labs, and medications vary. Confirm whether any baseline or follow-up testing is required, whether it is included, and whether the selected payment account treats the charge as eligible.
- Gala publishes useful prices, but the lowest GLP-1 rate requires a yearly subscription and the upfront annual charge is not shown.
- Microdosing and vaginal estradiol are consolidated under their active ingredients rather than presented as new medications.
- Compounding, Ozempic, NAD+, and sermorelin claims need more precise regulatory and evidence framing than Gala's marketing provides.